Skip to main
PODD

Insulet (PODD) Stock Forecast & Price Target

Insulet (PODD) Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 37%
Buy 47%
Hold 11%
Sell 5%
Strong Sell 0%

Bulls say

Insulet is a strong buy for long-term investors, as evidenced by its consistently strong financial results and growing market share in the diabetes management space. While competition and potential market erosion pose risks, Insulet's innovative technology and expansion into new markets should continue to drive double-digit revenue growth over the intermediate term. With multiple key product launches on the horizon and a growing prescriber base, Insulet has solid fundamentals and a favorable valuation compared to its medtech peers.

Bears say

Insulet is facing increasing competition in the insulin infusion market as other companies develop similar products. While the Omnipod system has seen growth, PODD's late entry into the closed loop system for Type 2 diabetes patients puts it behind competitors who have already launched their own versions. Additionally, despite positive growth in international markets, PODD's high valuation and competitive landscape pose risks for investors.

Insulet (PODD) has been analyzed by 19 analysts, with a consensus rating of Buy. 37% of analysts recommend a Strong Buy, 47% recommend Buy, 11% suggest Holding, 5% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Insulet and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Insulet (PODD) Forecast

Analysts have given Insulet (PODD) a Buy based on their latest research and market trends.

According to 19 analysts, Insulet (PODD) has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $336.89, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $336.89, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Insulet (PODD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.